Leukemia

Patients with advanced B-CLL double life expectancy in clinical trial

Published in Blood Weekly, June 13th, 2002

Life expectancy for patients with B cell chronic lymphocytic leukemia (B-CLL) doubled from eight to 16 months in a worldwide clinical trial of alemtuzumab (CampathR), according to lead researcher Dr. Michael J. Keating of the University of Texas M.D. Anderson Cancer Center, Houston.

The first full report of the pivotal clinical trial which led to accelerated FDA approval of alemtuzumab in May 2001 was published in the May 15, 2002 issue of Blood, the journal of the American Society of Hematology.

The article also presents follow-up data reporting a 32-month life expectancy among the 33% of trial enrollees who responded to alemtuzumab, said...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-06-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry